Skip to main content

Member info

    Medicine and Health Sciences
    Biomolecular Medicine
    Nanobody Lab
    Nanobody Lab, Technology Lane 75, 9052 Ghent, Belgium
    My lab specializes in the development and characterization of nanobodies against proteins considered potential drug targets. Camelidae nanobodies offer several advantages over conventional antibodies. They are much smaller, but have similar specificity and binding affinities as conventional antibodies. Nanobodies are coded by a single exon, and thus can be easily amplified by PCR and expressed in large amounts. My lab has extensive expertise in knocking out functions of proteins in cells using nanobodies. Using nanobody technology, we have studied proteins that regulate cancer cell migration, invasion and metastasis. Our specific contributions to the field are that we have been able to demonstrate that nanobodies act as high-affinity antagonists of protein function, without the need to alter protein expression, and we have succeeded in triggering protein loss-of-function by intracellular redistribution of endogenous proteins to different subcellular loci. Our lab uses a comprehensive approach, in which biochemistry, protein chemistry, cell biology and molecular biology are blended and integrated.

Jan Gettemans is full professor at the Department of Biomolecular Medicine, Faculty of Medicine and Health Sciences. His main focus is research on nanobodies (single domain antibodies) and their implementation in a diverse array of (bio)medical settings.

More in this category: